BOC Sciences, the US-based chemical vendor, announces to debut its — chiral ligand design technology for researchers involved with asymmetric catalysis on July 18, 2019, in a hope to identify and discover innovative drug candidates more effortlessly.
Since catalytic asymmetric synthesis has been one of the most active research areas in chemistry, the development of efficient chiral catalysts is therefore of paramount significance in asymmetric catalysis. In most cases, ligands design in asymmetric catalysis is guided by several simple concepts and principles. C2-symmetric ligands have dominated the field for a long time before the emergence and application of nonsymmetrical modular P, N-ligands, which have been successfully used in various metal-catalyzed reactions and, in many cases, have better performance than the P,P- or N,N-ligands.
“Despite the fact that many chiral ligands have been developed in the past decades, the most efficient catalysts are derived from a few core structures, called ‘privileged chiral catalysts’ such as chiral diphosphines, salen derivatives and bisoxazolines,” says Mr. Barron Jones, the Marketing Chief of BOC Sciences. “These privileged ligands families possess characteristics that lead to the induction of high stereoselectivities in their catalytic reactions. Consequently, the syntheses and design of chiral ligands have evolved into a rapidly growing area of research, attracting the attention of an increasing number of chemists from various disciplines.”
However, although impressive progress has been made in this field, the design of suitable chiral ligands for a particular application still remains a formidable task. The complexity of most catalytic processes makes it impossible to adopt a purely rational approach based on mechanistic and structural criteria. Therefore, most new chiral catalysts are still carried out empirically, relying more on chance, intuition, and systematic screening.
“Luckily, the mechanism of certain reactions such as Rh-catalyzed hydrogenation (1, 2) or Pd-catalyzed allylic substitution (3, 4). This allows at least a semi-rational approach to catalyst development. Our seasoned scientists are capable of greatly facilitating the development of new chiral ligands, using the useful general concepts developed during the last three decade, even in the absence of mechanistic information,” further adds Mr. Jones.
Currently, chiral N-heterocyclic carbene ligands, chiral anionic ligands and chiral phosphorus ligands are readily available at BOC Sciences. In fact, chiral ligand design is just part of a collective chiral synthesis methods, in addition to chiral auxiliaries, chiral building blocks, chiral resolution, etc.
About BOC Sciences
BOC Sciences is committed to becoming a trust-worthy brand. In the last decade and more, it strives to offer strategies and solutions to help resolving the industry’s most pressing drug development issues. To this end, it provides comprehensive medicinal chemistry services, custom synthesis such as building block synthesis, analysis/purification, formulation services for pharmaceutical companies engaged in drug discovery and research.
Release ID: 88898168